EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Myelofibrosis

Francesco Passamonti iD, Barbara Mora iD

Blood · 20.04.2023 · 141 (16) · 1954-1970

DOI: 10.1182/blood.2022017423 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Blood, erschienen am 20.04.2023. Verfasst von Francesco Passamonti und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, University of Insubria, Varese, Italy. Hauptthemen laut MEDLINE: Primary Myelofibrosis. Die Arbeit wurde bisher 158-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical phenotype of primary and post–polycythemia vera and postessential thrombocythemia myelofibrosis (MF) is dominated by splenomegaly, symptomatology, a variety of blood cell alterations, and a tendency to develop vascular complications and blast phase. Diagnosis requires assessing complete cell blood counts, bone marrow morphology, deep genetic evaluations, and disease history. Driver molecular events consist of JAK2V617F, CALR, and MPL mutations, whereas about 8% to 10% of MF are “triple-negative.” Additional myeloid-gene variants are described in roughly 80% of patients. Currently available clinical-based and integrated clinical/molecular-based scoring systems predict the survival of patients with MF and are applied for conventional treatment decision-making, indication to stem cell transplant (SCT) and allocation in clinical trials. Standard treatment consists of anemia-oriented therapies, hydroxyurea, and JAK inhibitors such as ruxolitinib, fedratinib, and pacritinib. Overall, spleen volume reduction of 35% or greater at week 24 can be achieved by 42% of ruxolitinib-, 47% of fedratinib-, 19% of pacritinib-, and 27% of momelotinib-treated patients. Now, it is time to move towards new paradigms for evaluating efficacy like disease modification, that we intend as a robust and unequivocal effect on disease biology and/or on patient survival. The growing number of clinical trials potentially pave the way for new strategies in patients with MF. Translational studies of some molecules showed an early effect on bone marrow fibrosis and on variant allele frequencies of myeloid genes. SCT is still the only curative option, however, it is associated with relevant challenges. This review focuses on the diagnosis, prognostication, and treatment of MF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Primary MyelofibrosisHumansPyrazolesNitrilesJanus Kinase 2PyrimidinesBridged-Ring Compounds

Substanzen

PyrazolesNitrilesJanus Kinase 2ruxolitinibPyrimidines11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,1…Bridged-Ring Compounds

Autor:innen und Institutionen

  • Department of Medicine and Surgery, University of Insubria, Varese, Italy.
  • Department of Oncology, ASST Sette Laghi, Ospedale di Circolo, Varese, Italy.

ORCID-Profile: Francesco Passamonti, Barbara Mora

Zitieren

APA

Passamonti, F., & Mora, B. (2023). Myelofibrosis. Blood, 141(16), 1954-1970. https://doi.org/10.1182/blood.2022017423

Vancouver

Passamonti F, Mora B. Myelofibrosis. Blood. 2023;141(16):1954-1970. doi:10.1182/blood.2022017423

BibTeX
@article{Passamonti2023,
  author = {Passamonti, Francesco and Mora, Barbara},
  title = {Myelofibrosis},
  journal = {Blood},
  year = {2023},
  volume = {141},
  number = {16},
  pages = {1954--1970},
  doi = {10.1182/blood.2022017423}
}
Kostenlos starten →